Biogen Idec made its 52-week high because of positive phase II clinical trial news about Adentri, its drug to prevent congestive heart failure. When you see a biotech stock like Biogen Idec making ...
Shares climbed 2.7% to $47.91 as Biogen also said it is scaling back the test of experimental heart-failure drug Adentri. Sonoco Hurt By Restructuring, Volume Drop Sonoco Products Co.'s (SON ...
Shares climbed 2.7% to $47.91 as Biogen also said it is scaling back the test of experimental heart-failure drug Adentri. Sonoco Hurt By Restructuring, Volume Drop Sonoco Products Co.'s (SON ...